Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Acute phase proteins

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    66 result(s) found for: Acute phase proteins. Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2011-003259-20 Sponsor Protocol Number: VenlaTrama_1.0 Start Date*: 2011-09-08
    Sponsor Name:University of Turku
    Full Title: Effect of duloxetine and venlafaxine on the pharmacokinetics and pharmacodynamics of oral tramadol: A three-phase randomized balanced cross-over study in healthy volunteers
    Medical condition: Acute postoperative pain and chronic pain syndromes
    Disease: Version SOC Term Classification Code Term Level
    14.0 10018065 - General disorders and administration site conditions 10066714 Acute pain LLT
    14.0 10018065 - General disorders and administration site conditions 10049475 Chronic pain LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-016998-15 Sponsor Protocol Number: TeriTrama_1.0 Start Date*: 2009-12-03
    Sponsor Name:University of Turku
    Full Title: Effect of terbinafine and itraconazole on the pharmacokinetics and pharmacodynamics of oral tramadol: A three-phase randomized balanced cross-over study in healthy volunteers
    Medical condition: Acute postoperative pain and chronic pain syndromes
    Disease: Version SOC Term Classification Code Term Level
    12.1 10066714 Acute pain LLT
    12.1 10049475 Chronic pain LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2010-020617-82 Sponsor Protocol Number: TicloTrama_1.0 Start Date*: 2010-08-12
    Sponsor Name:University of Turku
    Full Title: Effect of itraconazole and ticlopidine on the pharmacokinetics and pharmacodynamics of oral tramadol: A three-phase randomized balanced cross-over study in healthy volunteers
    Medical condition: Acute postoperative pain and chronic pain syndromes
    Disease: Version SOC Term Classification Code Term Level
    12.1 10066714 Acute pain LLT
    12.1 10049475 Chronic pain LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2013-001958-10 Sponsor Protocol Number: IMUNOR-201301 Start Date*: 2013-09-04
    Sponsor Name:ImunomedicA, a.s.
    Full Title: A Prospective, Randomized, Double-Blind, Placebo-controlled, Multicenter, Phase III Confirmatory Study Assessing Efficacy and Safety of the IMUNOR Therapy Versus Placebo in Children with Recurrent ...
    Medical condition: Recurrent Respiratory Tract Infections
    Disease: Version SOC Term Classification Code Term Level
    16.0 10042613 - Surgical and medical procedures 10067473 Immunomodulatory therapy PT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: SK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-004478-26 Sponsor Protocol Number: GHD/GHI Start Date*: 2006-01-13
    Sponsor Name:Karolinska universitetssjukhuset
    Full Title: Effects of growth hormone treatment to patients with partial growth hormone deficiency, with special emphasis on acute phase proteins and pro-inflammatory cytokines.
    Medical condition: Patients with various degrees of growth hormone (GH) insufficiency due to previously operated pituitary tumours.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-004270-43 Sponsor Protocol Number: AIEOP-BFMALL2009 Start Date*: Information not available in EudraCT
    Sponsor Name:Universitätsklinikum Schleswig-Holstein, Campus Kiel
    Full Title: International collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia
    Medical condition: acute lymphoblastic leukemia in children and adolescents 1 to <18 years of age
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10000845 Acute lymphoblastic leukemia LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) AT (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-003836-22 Sponsor Protocol Number: FLG-V001 Start Date*: 2019-12-11
    Sponsor Name:HUS Helsinki University Hospital
    Full Title: TWO-STAGE, TWO-ARM, OPEN-LABEL PHASE II STUDY OF VENETOCLAX IN COMBINATION WITH AZACYTIDINE IN ACUTE MYELOID LEUKEMIA PATIENTS SELECTED USING EX VIVO DRUG SENSITIVITY SCREENING
    Medical condition: Acute myeloid leukemia in patients who are non-fit for standard induction therapy (except acute promyelocytic leukemia) and present with de novo, secondary, released or refractory AML
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000880 Acute myeloid leukaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-001425-32 Sponsor Protocol Number: 14SM2359 Start Date*: 2015-01-13
    Sponsor Name:Imperial College London
    Full Title: RIVER - Research In Viral Eradication of HIV Reservoirs, A two-arm (proof of concept) randomised phase II trial
    Medical condition: HIV Infection
    Disease: Version SOC Term Classification Code Term Level
    18.0 10021881 - Infections and infestations 10000807 Acute HIV infection PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2009-017825-21 Sponsor Protocol Number: EC09/081 Start Date*: 2012-11-19
    Sponsor Name:INSTITUTO ARAGONÉS DE CIENCIAS DE LA SALUD
    Full Title: Prospective, randomised, double-blind study to evaluate the efficacy of treatment with melatonin in adult patients with severe sepsis or septic shock.
    Medical condition: Severe sepsis or septic shock.
    Disease: Version SOC Term Classification Code Term Level
    14.0 10021881 - Infections and infestations 10040070 Septic shock PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-002600-18 Sponsor Protocol Number: 43/2007/O/Sper Start Date*: 2007-06-05
    Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
    Full Title: EVALUATION OF THE RELATIONSHIP BETWEEN INFLAMMATION-PHYSICAL ACTIVITY AND THE ACTIVITY OF THE HYPOTHALAMIC-PITUITARY-ADRENAL AXIS
    Medical condition: Abdominal obesity with metabolic syndrome
    Disease: Version SOC Term Classification Code Term Level
    6.1 10052066 PT
    Population Age: Adults Gender: Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-004601-27 Sponsor Protocol Number: A5481008 Start Date*: 2013-07-17
    Sponsor Name:Pfizer Inc
    Full Title: A RANDOMIZED, MULTICENTER, DOUBLE-BLIND PHASE 3 STUDY OF PD-0332991 (ORAL CDK 4/6 INHIBITOR) PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER (+), HER2...
    Medical condition: "Estrogen receptor-positive (ER+), HER2 negative (HER2-) Advanced Breast Cancer (ABC)"
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed) BE (Completed) IE (Completed) FR (Completed) GB (GB - no longer in EU/EEA) ES (Ongoing) HU (Completed) IT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2013-002096-18 Sponsor Protocol Number: B2151007 Start Date*: 2014-08-13
    Sponsor Name:Pfizer Inc.,235 East 42nd Street, New York, NY 10017
    Full Title: AN OPEN-LABEL, MULTI-CENTER, RANDOMIZED PHASE 1B/2 STUDY OF PF05212384 PLUS 5-FLUOROURACIL-LEUCOVORIN-IRINOTECAN (FOLFIRI) VERSUS BEVACIZUMAB PLUS FOLFIRI IN METASTATIC COLORECTAL CANCER
    Medical condition: Metastatic Colorectal Cancer
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004864 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) IT (Prematurely Ended) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-000445-39 Sponsor Protocol Number: BET116183 Start Date*: 2013-12-20
    Sponsor Name:GlaxoSmithKline Research and Development Limited
    Full Title: A phase I/II open-label, dose escalation study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK525762 in subjects with relapsed, refractory hematologic ...
    Medical condition: Patients with relapsed and/or refractory haematological malignancies (lymphoma, leukemia, or multiple myeloma)
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10066481 Hematological malignancy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2010-019225-33 Sponsor Protocol Number: 31630 Start Date*: 2010-05-18
    Sponsor Name:
    Full Title: A Randomized Phase II Study Of Reirradiation And Hyperthermia Versus Reirradiation And Hyperthermia Plus Chemotherapy For Locally Recurrent Breast Cancer In Previously Irradiated Area
    Medical condition: All patients with a local regional recurrence of invasive breast cancer in previously irradiated area with measurable lesions not suitable for resection are eligible for this trial. Patients with m...
    Disease: Version SOC Term Classification Code Term Level
    12.1 10008456 Chemotherapy single agent systemic LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-003468-19 Sponsor Protocol Number: ADVL0912 Start Date*: 2020-08-14
    Sponsor Name:Children’s Oncology Group
    Full Title: ADVL0912: A PHASE 1/2 STUDY OF PF02341066, AN ORAL SMALL MOLECULE INHIBITOR OF ANAPLASTIC LYMPHOMA KINASE (ALK) AND C-MET, IN CHILDREN WITH RELAPSED/REFRACTORY SOLID TUMORS AND ANAPLASTIC LARGE CEL...
    Medical condition: malignant solid tumors including Inflammatory myofibroblastic tumor (IMT) and anaplastic large-cell lymphoma (ALCL)
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2007-007861-19 Sponsor Protocol Number: BE1116_3002 Start Date*: 2009-01-16
    Sponsor Name:CSL Behring GmbH
    Full Title: An open-label, randomized, multicenter Phase IIIb study to assess the efficacy, safety and tolerance of BERIPLEX® P/N compared with plasma for rapid reversal of coagulopathy induced by coumarin der...
    Medical condition: Therapy of major bleeding resulting from an acquired deficiency of vitamin K-dependent coagulation factors and proteins C and S due to use of oral anticoagulation therapy
    Disease: Version SOC Term Classification Code Term Level
    9.1 10009789 Coagulation factors decreased LLT
    9.1 10005103 Bleeding LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2020-001872-13 Sponsor Protocol Number: PTC299-VIR-015-COV19 Start Date*: 2021-01-15
    Sponsor Name:PTC Therapeutics, Inc.
    Full Title: Evaluation of the efficacy and safety of PTC299 in hospitalized subjects with COVID-19 (FITE19)
    Medical condition: Coronavirus disease 2019 (COVID-19)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10066740 Acute respiratory tract infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Prematurely Ended) FR (Completed) BE (Completed) GR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-000991-33 Sponsor Protocol Number: PI10/02877 Start Date*: 2012-07-13
    Sponsor Name:Instituto Aragonés de Ciencias de la Salud
    Full Title: Impact of melatonin in the pretreatment of organ donor and the influence in the evolution of liver transplant: a prospective, randomised double-blind study.
    Medical condition: Organ Transplant
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-002329-56 Sponsor Protocol Number: FISIO Start Date*: 2021-10-19
    Sponsor Name:Sociedad Española de Medicina Intensiva, Crítica y Unidades Coronarias (SEMICYUC)
    Full Title: Exploratory study to evaluate the efficacy and safety of nutritionally administering 1.5 g protein/kg/day vs. 1.0 g protein/kg/day in the catabolic phase of the critically ill patient on mechanical...
    Medical condition: Acquired Weakness in the Intensive Care Unit (DAUCI) of the critically ill patient.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10077255 Intensive care unit acquired weakness PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-005679-18 Sponsor Protocol Number: GMX04 Start Date*: 2011-12-07
    Sponsor Name:Bio Products Laboratory Limited
    Full Title: A Phase IV, Multicenter, Open-Label Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Gammaplex in Primary Immunodeficiency Diseases (PID) in Children and Adolescents
    Medical condition: Primary immunodeficiency diseases
    Disease: Version SOC Term Classification Code Term Level
    14.0 10005329 - Blood and lymphatic system disorders 10005329 Blood and lymphatic system disorders SOC
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: Removed from public view
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 18 14:51:56 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA